Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd has announced its Second Extraordinary General Meeting (EGM) for FY 2026-27, scheduled for July 31, 2026. The primary agenda is to consider and approve the issuance of up to 24,10,431 equity shares at a price of ₹115 per share on a preferential basis. This move is subject to shareholder approval and regulatory compliance, including SEBI (ICDR) Regulations, 2018. The meeting will be conducted via video conferencing, with July 24, 2026, set as the cut-off date for determining voting eligibility. The company aims to raise capital through this preferential allotment.

Asston Pharmaceuticals Ltd announced its Board of Directors has approved a preferential issue of up to 24,10,431 equity shares at ₹115 per share, aggregating ₹27.72 crore. The funds will be raised from non-promoter category investors on a cash basis. The company also approved convening an Extraordinary General Meeting (EGM) on July 31, 2026, to seek shareholder approval for this issuance. The Board meeting where these decisions were made commenced at 3:00 PM and concluded at 5:00 PM on July 02, 2026.

Asston Pharmaceuticals Ltd announced that its Board of Directors has approved a preferential issue of up to 24,10,431 equity shares at ₹115 per share, aggregating to ₹27.72 crore. These shares will be issued to non-promoter category investors on a cash basis, subject to shareholder and regulatory approvals. The company also announced the convening of an Extraordinary General Meeting (EGM) on July 31, 2026, to seek shareholder consent for this issuance. The board meeting took place on July 02, 2026, from 3:00 PM to 5:00 PM.

Asston Pharmaceuticals Ltd announced that its Board of Directors, in a meeting held on July 02, 2026, approved a preferential issue of up to 24,10,431 equity shares at ₹115 per share, aggregating to ₹27,71,99,565. These shares are to be issued to non-promoter category investors on a cash basis, subject to shareholder and regulatory approvals. The company also approved convening an Extraordinary General Meeting (EGM) on July 31, 2026, to seek member approval for the preferential allotment. The board meeting commenced at 3:00 PM and concluded at 5:00 PM.

Asston Pharmaceuticals Ltd announced the approval of a preferential issue of up to 24,10,431 equity shares at ₹115 per share, aggregating ₹27.71 crore. The shares will be issued to non-promoter category investors on a preferential basis for cash. This issuance is subject to shareholder and regulatory approvals. Additionally, the company approved convening an Extraordinary General Meeting (EGM) on July 31, 2026, to seek member approval for the preferential allotment. The board meeting was held on July 2, 2026, from 3:00 PM to 5:00 PM.

Asston Pharmaceuticals Ltd's Board of Directors has approved a preferential issue of up to 24,10,431 equity shares at ₹115 per share, aggregating ₹27.72 crore. The shares will be issued to non-promoter category individuals for cash. The company also announced an Extraordinary General Meeting (EGM) on July 31, 2026, to seek shareholder approval for this issuance. The board meeting took place on July 2, 2026, from 3:00 PM to 5:00 PM.

Asston Pharmaceuticals Ltd has announced a Board Meeting scheduled for Thursday, July 2, 2026. The primary agenda is to consider proposals for raising funds through various methods, including a preferential issue, subject to regulatory and shareholder approvals. In line with SEBI regulations and the company's code of conduct, the trading window for the company's securities will be closed from June 24, 2026, to July 4, 2026, inclusive. All connected and designated persons are advised against trading during this period.

Asston Pharmaceuticals Ltd has announced a Board of Directors meeting scheduled for July 2, 2026. The primary agenda item is to consider and approve proposals for raising funds through various methods, including preferential issue, subject to necessary regulatory and shareholder approvals. Additionally, the company will close its trading window from June 24, 2026, to July 4, 2026, to prevent insider trading during this period. All connected and designated persons are advised against trading in the company's securities during the window closure.

Asston Pharmaceuticals Ltd has announced its audited financial results for the year ended March 31, 2026. The Board of Directors approved the financial statements and results during a meeting held on May 29, 2026. The audit report, conducted by Panchal S K & Associates, provides an opinion that the financial results present a true and fair view in accordance with regulatory requirements and accounting standards.

Asston Pharmaceuticals Ltd. announced the approval of its audited financial results for the financial year ended March 31, 2026, during a Board of Directors meeting held on May 29, 2026. The meeting, conducted via video conferencing, commenced at 03:00 P.M. and concluded at 07:10 P.M. The approved financial statements and results, along with the audit report, comply with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Panchal S K & Associates, Chartered Accountants, conducted the independent audit, expressing an opinion that the financial results present a true and fair view in accordance with applicable accounting standards.